JP2016519124A5 - - Google Patents

Download PDF

Info

Publication number
JP2016519124A5
JP2016519124A5 JP2016511042A JP2016511042A JP2016519124A5 JP 2016519124 A5 JP2016519124 A5 JP 2016519124A5 JP 2016511042 A JP2016511042 A JP 2016511042A JP 2016511042 A JP2016511042 A JP 2016511042A JP 2016519124 A5 JP2016519124 A5 JP 2016519124A5
Authority
JP
Japan
Prior art keywords
formulation
concentration
seq
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016511042A
Other languages
English (en)
Japanese (ja)
Other versions
JP6470261B2 (ja
JP2016519124A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/058733 external-priority patent/WO2014177568A1/en
Publication of JP2016519124A publication Critical patent/JP2016519124A/ja
Publication of JP2016519124A5 publication Critical patent/JP2016519124A5/ja
Application granted granted Critical
Publication of JP6470261B2 publication Critical patent/JP6470261B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016511042A 2013-04-29 2014-04-29 抗il−4/抗il−13二特異的抗体製剤 Active JP6470261B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361816899P 2013-04-29 2013-04-29
US61/816,899 2013-04-29
EP14305160 2014-02-05
EP14305160.5 2014-02-05
PCT/EP2014/058733 WO2014177568A1 (en) 2013-04-29 2014-04-29 Anti-il-4/anti-il-13 bispecific antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019004836A Division JP2019070025A (ja) 2013-04-29 2019-01-16 抗il−4/抗il−13二特異的抗体製剤

Publications (3)

Publication Number Publication Date
JP2016519124A JP2016519124A (ja) 2016-06-30
JP2016519124A5 true JP2016519124A5 (enExample) 2017-06-22
JP6470261B2 JP6470261B2 (ja) 2019-02-13

Family

ID=50159179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016511042A Active JP6470261B2 (ja) 2013-04-29 2014-04-29 抗il−4/抗il−13二特異的抗体製剤

Country Status (16)

Country Link
US (1) US10005835B2 (enExample)
EP (1) EP2991678B1 (enExample)
JP (1) JP6470261B2 (enExample)
KR (1) KR102307257B1 (enExample)
CN (1) CN105339004B (enExample)
AU (1) AU2014261497B2 (enExample)
CA (1) CA2910693C (enExample)
CL (1) CL2015003193A1 (enExample)
IL (1) IL242372B2 (enExample)
MX (1) MX378502B (enExample)
MY (1) MY178837A (enExample)
PH (1) PH12015502441A1 (enExample)
RU (1) RU2690850C2 (enExample)
SG (2) SG11201508682RA (enExample)
TW (1) TWI679019B (enExample)
WO (1) WO2014177568A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2686014A1 (en) 2011-03-16 2014-01-22 Sanofi Uses of a dual v region antibody-like protein
CA2910584A1 (en) 2013-05-03 2014-11-06 Selecta Biosciences, Inc. Use of immunosuppressants attached to synthetic nanocarriers to enhance levels of cd4+ regulatory t cells
TW201628647A (zh) 2014-06-27 2016-08-16 賽諾菲公司 抗-il4-il13雙特異性抗體
KR101776879B1 (ko) 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
BR112018014123A2 (pt) * 2016-01-12 2018-12-11 Dr. Reddy's Laboratories Limited formulação farmacêutica aquosa estável.
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
KR102471458B1 (ko) 2016-12-28 2022-11-25 제이씨알 파마 가부시키가이샤 동결건조 제제
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JOP20190255A1 (ar) 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
EP3624846B1 (en) 2017-05-16 2024-08-07 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類CEACAM5抗體Fab片段
BR112020023420A8 (pt) 2018-05-17 2022-07-05 Astellas Pharma Inc Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
WO2020053301A1 (en) * 2018-09-11 2020-03-19 Ichnos Sciences S.A. Compositions comprising a bispecific antibody, bufffer and one or more stabilizing agents
SG11202102995PA (en) * 2018-10-01 2021-04-29 Amgen Inc Methods for reducing aggregation of bispecific antibodies
EP3865154A4 (en) 2018-10-10 2022-11-09 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY FAB FRAGMENT COMPLEX AT LABELED ANTI-HUMAN SITE
KR102131519B1 (ko) * 2018-10-30 2020-07-07 가톨릭대학교 산학협력단 간암 전이 진단 또는 예후 예측용 바이오마커 및 이의 용도
CN116726362A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
CN120204385A (zh) 2019-05-24 2025-06-27 赛诺菲 治疗系统性硬化症的方法
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN115484931A (zh) * 2020-03-11 2022-12-16 西莱克塔生物科技公司 与合成纳米载体相关的方法和组合物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク. 免疫したゼノマウス(XenoMouse)に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2464695A1 (en) 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses
US20040023338A1 (en) 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
US20060148009A1 (en) 2004-10-12 2006-07-06 Xencor, Inc. Prediction and assessment of immunogenicity
CN101600457B (zh) * 2007-01-09 2014-01-08 惠氏公司 抗il-13抗体调配物和其用途
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2011017070A1 (en) 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
EP2547365A1 (en) * 2010-03-17 2013-01-23 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
EP2686014A1 (en) * 2011-03-16 2014-01-22 Sanofi Uses of a dual v region antibody-like protein
TWI803876B (zh) 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
ES2806146T3 (es) * 2011-09-22 2021-02-16 Amgen Inc Proteínas de unión al antígeno CD27L
CN102961745B (zh) * 2012-09-27 2015-02-18 苏州康聚生物科技有限公司 抗体组合物制剂及其应用

Similar Documents

Publication Publication Date Title
JP2016519124A5 (enExample)
RU2015150149A (ru) Составы на основе биспецифических антител к il-4/il-13
TWI853077B (zh) 新型抗cd39抗體
WO2021244089A1 (zh) 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用
AU2016363455B2 (en) Full human antibody against respiratory syncytial virus
PE20181952A1 (es) Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos
HRP20191219T1 (hr) Molekule protutijela koje imaju specifičnost za ljudski ox40
RU2014101707A (ru) АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
JP2012254092A5 (enExample)
JP2011527899A5 (enExample)
JP2018521638A5 (enExample)
JP2019536806A5 (enExample)
JP2012525829A5 (enExample)
IL299072A (en) Antibodies and methods of use thereof
PE20121646A1 (es) Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica
RU2019132843A (ru) Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение
RU2018102606A (ru) Молекулы, связывающиеся с psl pseudomonas, и пути их применения
JP2012518425A5 (enExample)
JP2016509009A5 (enExample)
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
AR058955A1 (es) Inmunglobulinas que se unen a interleuquina 13
JP2011527902A5 (enExample)
JP2014519334A5 (enExample)
EA201190275A1 (ru) Белок, связывающий интерлейкин-13 (il-13)
AR075849A1 (es) Moleculas de anticuerpos que tienen especificidad de union por il-13 humana